Stifel analyst Benjamin J. Burnett reiterates a "Buy" rating on shares of Kinnate Biopharma (NASDAQ: KNTE), and increases his price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE